The molecular mechanisms that underpin angiogenesis in breast cancer are becoming clearer, particularly in relation to hypoxia. Some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. The authors of this Review discuss the potential of components of the angiogenic pathway as prognostic and predictive factors in breast cancer, and comment on the challenges facing the clinical development and optimum use of these agents.
- Susana Banerjee
- Mitch Dowsett
- Lesley-Ann Martin
